TrialGynecologic oncology2020

Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract.

Michael Frumovitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.